Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Company Overview

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Key Stats

• Today's Range: $1.04 to $1.11
• 50-Day Range: $0.86 to $1.22
• 52-Week Range: $0.81 to $1.76
• Volume: 58,464 shs
• Average Volume: 128,245 shs
• Market Capitalization: $22.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Enlivex Therapeutics Stock Analysis - MarketRank™

Enlivex Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 586th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Enlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enlivex Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enlivex Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enlivex Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.51% of the float of Enlivex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enlivex Therapeutics has recently decreased by 8.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enlivex Therapeutics does not currently pay a dividend.

Dividend Growth

Enlivex Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.51% of the float of Enlivex Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enlivex Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enlivex Therapeutics has recently decreased by 8.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.02% of the stock of Enlivex Therapeutics is held by institutions.

ENLV Stock Analysis - Frequently Asked Questions

How have ENLV shares performed this year?

Enlivex Therapeutics' stock was trading at $1.17 at the beginning of the year. Since then, ENLV stock has decreased by 10.3% and is now trading at $1.05.
View the best growth stocks for 2025 here.

How were Enlivex Therapeutics' earnings last quarter?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its quarterly earnings results on Monday, March, 31st. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07.

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 5/07/2025
• Next Earnings (Estimated): 6/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENLV
• CIK: 1596812
• Web: www.enlivex.com
• Phone: (728) 662-3301
• Fax: 972-2620-8070
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $13.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +852.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,070,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.57%
• Return on Assets: -58.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.71
• Quick Ratio: 9.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.62 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 21,406,000
• Free Float: 18,777,000
• Market Cap: $22.48 million
• Optionable: Optionable
• Beta: 0.76